Physician profile
Maria E Posada
NPI 1992928329
$2,483.14
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,191 · 2022: $865 · 2023: $379 · 2024: $48.12.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $427.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $426.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $440.48 | 2021-2023 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $426.51 | 2021-2023 | Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $248.03 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $153.24 | 2021-2023 | Xifaxan |
| Pfizer INC. | $135.23 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $135.09 | 2021-2022 | |
| Amarin Pharma, INC. | $102.15 | 2021 | |
| Astellas Pharma US INC | $101.63 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $70.52 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $59.29 | 2022 | |
| Abbott Laboratories | $55.80 | 2021-2023 | Freestyle Libre 2 |
| Lilly USA, LLC | $52.01 | 2022-2023 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.23 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $49.72 | 2022 | |
| Abbvie INC. | $49.03 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $48.12 | 2024 | Pico 14, Renasys Touch |
| Eisai INC. | $45.91 | 2021 | |
| Glaxosmithkline, LLC. | $43.20 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $37.40 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $30.73 | 2022 | |
| Lundbeck LLC | $24.21 | 2023 | Rexulti |
| Corium, LLC | $22.48 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $22.04 | 2023 | Rexulti, Abilify Maintena |
| Insmed, INC. | $19.74 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.36 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.37 | 2023 | Quviviq |
| Sanofi-Aventis U.S. LLC | $14.02 | 2021 | |
| Esperion Therapeutics, INC. | $11.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Posada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.